Adverse Event Management and Dosing of Immunotherapies and Tyrosine Kinase Inhibitors

As treatment regimens have become more potent, effective toxicity management is essential. Panelists highlight common adverse events associated with immune checkpoint blockade and tyrosine kinase inhibitors, including fatigue, diarrhea, hepatic enzyme elevation, and hypertension. Early identification and proactive management of these effects enable continued therapy and reduce interruptions.

The discussion outlines practical approaches to dose adjustments, temporary holds, and supportive measures. Coordination between oncology providers, primary care, and subspecialists ensures that patients receive comprehensive management for treatment-related complications. Regular monitoring and patient education are emphasized as key components of safe and effective care.

By standardizing toxicity protocols and fostering patient engagement, clinicians can optimize treatment adherence and outcomes, maintaining efficacy while minimizing long-term burden.